Cision PR Newswire

Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection -- -- Robust neutralizing antibody responses across RSV, hMPV and PIV3 in Phase 2 recapitulates Phase...

Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

SHANGHAI, Sept. 7, 2026 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock...

FDI World Dental Federation launches Generation Smile, the oral health movement for all

Generation Smile is a generation unlike any other. It isn't defined by the year...

China Xplained | The China Squeeze, or the China Opportunity?

GUANGZHOU, China, Sept. 6, 2026 /PRNewswire/ -- This is a news report from South: ...

Futu Trustee Is Recognized as “Hong Kong Best Trust Administrator”

HONG KONG, April 2, 2025 /PRNewswire/ -- Futu Trustee was honoured as the "Hong Kong Best Trust Administrator" at the 2025 Euromoney Private Banking Awards, hosted...

Fosun International 2024 Annual Results Presentation: Aiming for RMB10 Billion in Future Industrial Operation Profit

HONG KONG and SHANGHAI, April 2, 2025 /PRNewswire/ -- On 1 April 2025, Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with...

Invitation to presentation of EQT AB’s Q1 Announcement 2025

STOCKHOLM, April 2, 2025 /PRNewswire/ -- EQT AB's Q1 Announcement 2025 will be published on Wednesday 16 April 2025 at approximately 07:00 CEST. EQT...